🇺🇸 FDA
Patent

US 12336983

Inhibition of crystal growth of roflumilast

granted A61KA61K31/44A61K45/06

Quick answer

US patent 12336983 (Inhibition of crystal growth of roflumilast) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARCUTIS BIOTHERAPEUTICS, INC.
Grant date
Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K31/44, A61K45/06, A61K47/10, A61K9/0014